Jeremy Grantham Cytom X Therapeutics, Inc. Call Options Transaction History
Grantham, Mayo, Van Otterloo & Co. LLC
- $31.8 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTMX
# of Institutions
94Shares Held
123MCall Options Held
305KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$47.9 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$38 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$32.2 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$29 Million0.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.08MShares$27.7 Million0.04% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $226M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...